Tethys Bioscience, Inc

Our Mission To create and commercialize innovative blood tests that accurately assess imminent disease risk, enabling healthcare providers to preempt the onset of chronic cardiometabolic conditions by focusing healthcare resources on those patients who will benefit the most from early and aggressive intervention. Our History Tethys was established in 2005 with a singular focus: to reduce the clinical and economic burden of preventable, chronic diseases by preempting their development. Recognizing the urgent need for better ways to address one of the most debilitating and economically devastating preventable diseases in the world, the company’s founders first turned their attention to type 2 diabetes, pursuing the development of a novel approach designed to transform the way diabetes and other cardiometabolic diseases are assessed and treated. Tethys proudly unveiled its first product, the PreDx® Diabetes Risk Score. PreDx® DRS is a simple fasting blood test that combines multiple blood-borne markers and a proprietary algorithm to deliver an unprecedented level of risk stratification for patients at risk for type 2 diabetes. Recent studies show that a decrease in PreDx DRS within months of initiation of intervention is correlated with a decreased risk of diabetes years later. Tethys's business is focused on building a sustainable cardiometabolic diagnostics business by expanding its commercial infrastructure and establishing partnerships to increase physician use. Today Tethys closed it's doors and assets were acquired by Human Diagnostics Labs in 2014.